AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Insight Partners hit by cyber attack with possible data leaks
2
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
3
Adi Dangot Zukovsky joins Ibex Investors as partner following fund’s leadership shift
4
Riskified cuts staff as struggles continue
5
How Intel ruined an Israeli startup it bought for $2B—and lost the AI race
More news

Teva

20 stories about Teva
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva’s Copaxone Successors Are Still Far From Success

05.05.19|Hezi Sternlicht
Teva’s first quarter report for 2019, published Thursday, shows that while the drugmaker is progressing with its financial rehabilitation program, its net debt to EBITDA ratio is leaving the company in dangerous waters
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
אתר טבע כפר סבא

Teva Discontinues Development of Cluster Headache Drug

24.04.19|Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
מטה טבע פתח תקווה

FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose

21.04.19|Lilach Baumer
Commonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Execs Topped TASE's High Earners List for 2018

18.04.19|Gil Kalian
With nearly $34 million added to the bank, Teva’s CEO Kåre Schultz was the highest earning executive on the Tel Aviv Stock Exchange last year
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Market Indifferent to European Approval of Teva's Migraine Drug

02.04.19|Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
מפעל טבע הר חוצבים ירושלים

Bidder Contests Teva Sale of Jerusalem Facility

31.03.19|Amitai Gazit and Lilach Baumer
Earlier this month, Teva agreed to sell the land tenure rights of its two Jerusalem factories, set to close by the end of 2019, for a combined $77 million
מטה טבע פתח תקווה

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

24.03.19|CTech
Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
מפעל חברת טבע הר חוצבים ירושלים

Teva Selling Jerusalem Land Tenure Rights Ahead of Factory Closures

20.03.19|Golan Hazani
Teva currently has two manufacturing plants in Jerusalem, both slated for closure by the end of 2019
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
דוד לוסטיג סמנכ"ל בכיר מנהל התפעול טבע ישראל

Senior Vice President David Lustig Leaving Teva After 25 Years

19.03.19|Tzally Greenberg
Lustig will be replaced by Miran Denac, currently senior vice president and cluster manager for central and Western Europe operations
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Morgan Stanley Downgrades Teva From Overweight to Equal Weight

07.03.19|Hezi Sternlicht
The bank upgraded Teva to overweight in November, setting a target price of $27, at the time a 20% premium on the company’s trading price
קאר שולץ מנכל טבע

Teva’s Schultz is Running Out of Rope

14.02.19|Hezi Sternlicht
In the fourth quarter and annual earnings reported by the company Wednesday, Teva missed analyst consensus for non-GAAP earnings per share, and shareholders seem to be losing patience
מנכ"ל טבע החדש קור שולץ 2

Teva to Close 11 More Manufacturing Facilities in 2019

14.02.19|Lilach Baumer
The drugmaker published its fourth quarter and annual reports Wednesday, dropping almost 8% on NYSE after forecasting a steep cut in profits for 2019
קאר שולץ מנכל טבע

Teva Falls in Pre-Market Following Low-Profit Forecasts for 2019

13.02.19|Lilach Baumer
The drugmaker forecasts revenues of $17 billion to 17.4 billion for 2019, much lower than analyst expectations
מפעל טבע קריית שמונה

Teva to Sell Northern Israeli Facility to Private Equity Fund FIMI

06.02.19|Tzally Greenberg
Teva unveiled a reorganization plan in December 2017 to ameliorate its debilitating debt, announcing its intention to close or sale facilities and layoff 25% of employees by 2019
הפגנה מפגינים פיטורים טבע אשדוד

Teva Signs Deal to Sell Closed Israeli Factory

03.02.19|Lilach Baumer
In December 2017, Teva announced plans to sell or close many of its manufacturing facilities and let 25% of global employees go as part of a debt management plan
מנכ"ל טבע החדש קור שולץ 2

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports

27.01.19|Lilach Baumer
In October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
קאר שולץ מנכל טבע

Israel Tax Authority to Demand Over NIS One Billion From Teva

16.01.19|Omri Milman and Tomer Ganon
Teva did not pay taxes in Israel for the decade preceding 2014, saving NIS 20.6 billion in tax benefits
Previous ArticlesMore Articles